



Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

SAA Measure Description¹

Assesses adults 18 years of age and older who have schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period.

Why is SAA Important?¹

Schizophrenia is a chronic and disabling psychiatric disorder that requires ongoing treatment and monitoring. Symptoms include hallucinations, illogical thinking, memory impairment, and incoherent speech. Medication non-adherence is common and a major concern in the treatment of schizophrenia. Using antipsychotic medications as prescribed reduces the risk of relapse or hospitalization.

Best Practices

- ✓ Review pharmacy locations where a patient gets refills and identify transportation needs (if any).
- ✓ Review patients access to prescribed medications and capacity for purchasing/affording medications.
- ✓ Coordinate care between BH provider and PCP requesting test results, communicating test results or scheduling an appointment for testing/screening.
- ✓ Improve medication education by informing patient why they are taking a medication, medication targets, side effects and importance of adherence.
- ✓ Follow up with phone calls to help ensure adherence and to re-evaluate the patient's understanding.

Numerator Compliance²

The number of members who achieved a PDC of at least 80% for their antipsychotic medications during the measurement year.

Numerator Codes²

Refer to next page for the list of medications

Data Collection Method²

Administrative (Claims)



Trillium Percentages/NCQA National Averages¹

SAA	Calendar Year	Trillium	NCQA National Average
Adherence to Antipsychotic Medications for Individuals with Schizophrenia Rate	2022	67.1	59.8
	2021	65.2	59.7

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: ncqa.org/hedis/measures

² Source: HEDIS MY 2024 Tech Specs Manual Vol. 2

SAA Numerator Medications²

Description	Prescription	
Long-acting injections 14 days supply	Risperidone (excluding Perseris®)	
Long-acting injections 28 days supply	Aripiprazole Aripiprazole lauroxil Fluphenazine decanoate	Haloperidol decanoate Olanzapine Paliperidone palmitate
Long-acting injections 30 days supply	Risperidone (Perseris®)	
Miscellaneous antipsychotic agents (oral)	Aripiprazole Asenapine Brexipiprazole Cariprazine Clozapine Haloperidol Iloperidone Loxapine	Lumateperone Lurasidone Molindone Olanzapine Paliperidone Quetiapine Risperidone Ziprasidone
Phenothiazine antipsychotics (oral)	Chlorpromazine Fluphenazine Perphenazine	Prochlorperazine Thioridazine Trifluoperazine
Psychotherapeutic combinations (oral)	Amitriptyline-perphenazine	
Thioxanthenes (oral)	Thiothixene	

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: [ncqa.org/hedis/measures](https://www.ncqa.org/hedis/measures)

² Source: HEDIS MY 2024 Tech Specs Manual Vol. 2